Full-Time

Clinical Sales Manager

Seattle

Updated on 8/21/2026

Karius

Karius

201-500 employees

Non-invasive liquid biopsy for infectious pathogens

Compensation Overview

$118.3k - $177.5k/yr

Seattle, WA, USA

Remote

Remote within the Pacific Northwest territory; travel up to 70% across Alaska, Idaho, Montana, Oregon, Washington, and Hawaii.

Bachelor's, Master's, MBA

Category
Sales & Account Management (1)
Required Skills
Sales
Machine Learning
Salesforce
Microbiology

Get referred to Karius

See people who can refer or advise you

Requirements
  • A bachelor's degree is required; an advanced degree or Master of Business Administration is a plus.
  • At least 5 years of sales or business development experience in life sciences, biotechnology, medical devices, diagnostic equipment, and/or pharmaceutical industries.
  • A valid driver's license is required.
  • Previous success introducing transformational, novel products or services to physicians and hospitals that changed clinical practice before significant peer-reviewed publications or guideline inclusion.
  • A robust network of existing relationships in hospitals and health systems, including microbiology laboratories, send-out laboratories, physician groups, C-level executives, and clinical-function administrators.
  • Strong territory vision and planning capabilities.
  • Strong business acumen, analytical aptitude, and problem-solving skills.
  • The ability to develop relationships with C-level executives, physicians, and laboratory directors while building credibility through subject-matter and industry expertise.
  • A demonstrated record of top sales achievement and meeting or exceeding sales objectives.
  • Experience with multi-level account management.
  • The ability to multitask and work in a fast-paced, ambiguous, growth-oriented environment.
  • The ability to set priorities, allocate resources, take accountability, and achieve results.
  • Strong presentation and negotiation skills, including the ability to manage and facilitate discussions with small and large groups.
  • Personal ethics, integrity, confidentiality, and the ability to build trusting and professional relationships.
Responsibilities
  • Grow sales revenue and test volume in the territory by establishing new hospital business and increasing volume in existing hospitals.
  • Engage hospital stakeholders involved in decisions to implement new diagnostic tests.
  • Collaborate with Inside Sales, Customer Success, Medical Affairs, and Marketing to achieve territory and company goals.
  • Develop thought leaders and early adopters for the new approach to infectious disease diagnosis.
  • Help establish the foundation and culture of a world-class commercial organization.
  • Build, manage, and nurture a market-based regional territory consisting of hospital and health system accounts.
  • Prioritize and segment hospital and health system accounts to maximize opportunity and growth.
  • Present product features and benefits to key stakeholders and clinical call points using consultative sales techniques, including qualifying leads, assessing needs, supporting evaluations, and closing.
  • Manage early evaluations to activate initial adoption of the Karius test and solutions and drive increased utilization over time.
  • Serve as a subject-matter expert for clinicians regarding the science and technology of the Karius test and its clinical use.
  • Explain the merits and value of the proprietary test and differentiate it from competitors.
  • Build relationships, educate stakeholders, and drive consensus across prospective and existing partners.
  • Develop trusted-advisor relationships and remain accountable for demonstrating return on investment to partner accounts through regular interaction and utilization review.
  • Secure contracts and agreements when necessary or optimal to formalize long-term partner relationships and improve revenue predictability.
  • Manage and secure renewals of partner agreements.
  • Collaborate with Sales, Marketing, and Product leadership to provide market feedback.
  • Partner and co-present with Clinical and Medical Affairs teams, including Medical Science Liaisons, during remote and in-person partner interactions and manage follow-up.
  • Collaborate with Customer Success to onboard accounts, share feedback, address risks and concerns, manage expectations, promote successes, and monitor partner health.
  • Partner with Marketing to identify and co-manage regional meeting opportunities, develop Key Opinion Leader panels, and conduct local market activities.
  • Participate in sales meetings, training programs, conventions, and industry trade shows as required.
  • Complete paperwork and administrative duties, including Salesforce documentation, expense reports, and speaker program information.
Desired Qualifications
  • An advanced degree.
  • A Master of Business Administration.

Karius provides rapid, non-invasive infectious-disease diagnostics using the Karius Test, a liquid biopsy that detects over 1,000 pathogens from a single blood sample. The test analyzes microbial cell-free DNA circulating in the bloodstream, using advanced genomics and artificial intelligence to identify pathogens. It operates on real-time genomic data and a constantly updated reference database, enabling clinicians to diagnose infections without multiple invasive tests. Unlike traditional methods, Karius combines a broad pathogen panel with machine-learning analysis to deliver faster results and reduce unnecessary procedures. The company's goal is to help healthcare providers diagnose infections quickly, improve patient outcomes, and reduce healthcare costs by offering a faster, less invasive diagnostic option.

Company Size

201-500

Company Stage

Series C

Total Funding

$345M

Headquarters

Redwood City, California

Founded

2014

Get referred to Karius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BARDA awarded Karius a contract August 8, 2024 for agnostic pathogen detection.
  • Karius Test entered 2023 Duke-ISCVID endocarditis criteria, strengthening clinician acceptance.
  • Karius expanded access via Mayo Clinic Laboratories, speeding reporting within 24 hours of arrival.

What critics are saying

  • Blue Cross Blue Shield of Michigan upheld Karius denial December 16, 2025 as investigational.
  • Humana Kentucky Medicaid required prior authorization for Karius test on June 29, 2026.
  • FDA authorization lag keeps Karius dependent on LDT status until device clearance arrives.

What makes Karius unique

  • Karius Focus | BAL launched nationwide April 28, 2025 for immunocompromised pneumonia.
  • Karius earned FDA Breakthrough Device designation May 16, 2024 for lung infections.
  • Karius now reaches 600 hospitals through Mayo Clinic Laboratories collaboration April 23, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-2%

2 year growth

0%
Business Wire
May 16th, 2024
Karius Test® Receives Fda Breakthrough Device Designation To Aid In The Diagnosis Of Infectious Disease

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc., a leader in genomic diagnostics for infectious diseases, announced today that the Karius Test® has been granted designation as a Breakthrough Device from The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), for use in the diagnosis and management of immunocompromised patients with suspected lung infections including lower respiratory infection and pneumonia. “The Karius Test is commercially available nationwide as a laboratory developed test. We are seeking FDA marketing authorization of the Karius Test for lung infections in immunocompromised patients because improved diagnostic tests are urgently needed for these patients,” stated Brad Perkins, M.D., Chief Medical Officer of Karius. “As noted in the American Thoracic Society (ATS) Workshop Report for Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria,1 lung infections have high morbidity and mortality in immunocompromised patients, which is why advances in technologies like metagenomic sequencing used for the Karius Test are vital in improving the diagnosis and treatment of these patients.”. The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these innovative medical devices

Forbes
May 8th, 2024
Innovationrx: Deepmind Unveils Its New Protein-Folding Ai Model Alphafold 3

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. A protein folding prediction in response to a small molecule generated by AlphaFold 3.Isomorphic LabsToday, Deepmind announced the launch of AlphaFold 3, the next generation of its AI software for structural biology, which has enabled thousands of researchers to predict the complicated chemical interactions involved with proteins. One major difference in the new iteration of the program: instead of just predicting protein folding, it predicts the interactions of other biological molecules as well including DNA, RNA and small molecules. The company published the accuracy of its predictions in the journal Nature.In addition to the new capabilities–which even includes the ability to make predictions based on epigenetic changes to DNA–the company has also launched AlphaFold Server, a web service that enables researchers to generate biochemical models without having to install the system itself from open source code, as was the case with previous iterations. Something else new is that AlphaFold now works with diffusion models – which are popularly known for being used by AI systems that generate images from text prompts – in place of some of its previous structural models.“The response to AlphaFold 2 was more than I could have ever imagined in terms of the kind of creativity and what the research community has done with it,” Deepmind research director John Jumper said at a press briefing

Citybiz
May 3rd, 2024
Karius Secures $100M in Series C

Karius, Inc., a genomic diagnostics company, has raised $100 million in a Series C funding round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare. The funds will be used to expand the reach of the Karius Test®, which detects over 1,000 pathogens from a single blood sample, beyond 400 U.S. hospitals. The company also added three new board members, including Alex Morgan from Khosla Ventures, Joep Muijrers from Gilde Healthcare, and Andrew Booth from 5AM Ventures.

RamaOnHealthcare
May 2nd, 2024
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test

Karius secures $100M to expand non-invasive pathogen blood Test.

Business Wire
May 2nd, 2024
Karius Secures $100M for Genomic Diagnostics Expansion

Karius, Inc. has raised $100M in Series C funding, co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from Seventure Partners and others. The funds will expand the reach of the Karius Test®, a genomic diagnostic test for infectious diseases, beyond 400 U.S. hospitals. The investment also supports research into microbial cell-free DNA technology. Additionally, Karius announced three new board members.